Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ORCHID PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ORCHID PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
ORCHID PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 439 | 319 | - | |
Low | Rs | 273 | 230 | - | |
Sales per share (Unadj.) | Rs | 163.1 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 13.5 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 27.0 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 168.7 | 74.5 | - | |
Shares outstanding (eoy) | m | 40.82 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.2 | 2.9 | 75.4% | |
Avg P/E ratio | x | 26.3 | -11.5 | -228.9% | |
P/CF ratio (eoy) | x | 13.2 | -13.9 | -95.3% | |
Price / Book Value ratio | x | 2.1 | 3.7 | 57.2% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 14,522 | 46,340 | 31.3% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 654 | 2,908 | 22.5% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,659 | 16,016 | 41.6% | |
Other income | Rs m | 194 | 112 | 173.2% | |
Total revenues | Rs m | 6,853 | 16,128 | 42.5% | |
Gross profit | Rs m | 1,235 | -2,775 | -44.5% | |
Depreciation | Rs m | 548 | 691 | 79.3% | |
Interest | Rs m | 329 | 434 | 75.8% | |
Profit before tax | Rs m | 552 | -3,788 | -14.6% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 237 | 0.0% | |
Profit after tax | Rs m | 552 | -4,036 | -13.7% | |
Gross profit margin | % | 18.5 | -17.3 | -107.0% | |
Effective tax rate | % | 0 | -6.2 | -0.0% | |
Net profit margin | % | 8.3 | -25.2 | -32.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 5,010 | 11,730 | 42.7% | |
Current liabilities | Rs m | 3,719 | 6,600 | 56.3% | |
Net working cap to sales | % | 19.4 | 32.0 | 60.5% | |
Current ratio | x | 1.3 | 1.8 | 75.8% | |
Inventory Days | Days | 57 | 111 | 51.7% | |
Debtors Days | Days | 1,180 | 124 | 951.7% | |
Net fixed assets | Rs m | 7,242 | 6,838 | 105.9% | |
Share capital | Rs m | 408 | 74 | 548.9% | |
Net worth | Rs m | 6,886 | 12,571 | 54.8% | |
Long term debt | Rs m | 1,488 | 4,418 | 33.7% | |
Total assets | Rs m | 12,252 | 23,747 | 51.6% | |
Interest coverage | x | 2.7 | -7.7 | -34.6% | |
Debt to equity ratio | x | 0.2 | 0.4 | 61.5% | |
Sales to assets ratio | x | 0.5 | 0.7 | 80.6% | |
Return on assets | % | 7.2 | -15.2 | -47.4% | |
Return on equity | % | 8.0 | -32.1 | -25.0% | |
Return on capital | % | 10.5 | -19.8 | -53.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 183 | 1,367 | 13.4% | |
From Investments | Rs m | -312 | -420 | 74.4% | |
From Financial Activity | Rs m | 312 | 4,009 | 7.8% | |
Net Cashflow | Rs m | 183 | 4,957 | 3.7% |
Compare ORCHID PHARMA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare ORCHID PHARMA With: SHREE GANESH REMEDIES MEDPLUS HEALTH SERVICES GRANULES INDIA PHAARMASIA SUVEN PHARMACEUTICALS
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.